Back to search

United States· US:70000-0243_941e2a47-36d1-4ebd-938e-759b3ea9e1e4

Leader Urinary Pain Relief

A phenazopyridine product containing phenazopyridine hydrochloride, registered in United States by Cardinal Health. The same ATC class is registered in 2 of our 19 countries.

ATC G04BX06US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedLeader Urinary Pain ReliefATCG04BX06REGISTER NO.US:70000-0243_941e2a4…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Phenazopyridine is registered in 2 of 19 countries.

Countries holding a registration under ATC G04BX06 (phenazopyridine), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 1 of them publish a price we can compare per daily dose

Phenazopyridine · ATC G04BX06

2 / 19 countries

  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
PHENAZOPYRIDINE HYDROCHLORIDE
Manufacturer
Cardinal Health
Country
United States (US)
ATC code
G04BX06
ATC class
Phenazopyridine
Defined daily dose
0.6 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    7000002431
    1 BLISTER PACK in 1 CARTON (70000-0243-1) / 30 TABLET in 1 BLISTER PACK
  • ndc11
    70000-0243-1

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

40 interactions on record for phenazopyridine.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Phenazopyridine · interactions on record

40 records

  • 4 severe
  • 36 moderate

Most severe, free to view

  • LeflunomidL04AA13severe
  • TeriflunomidL04AA31severe
  • LeflunomideL04AK01severe
  • TeriflunomideL04AK02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Phenazopyridine in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All phenazopyridine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e981a9bf-37ca-4812-b04d-006a61bd56bc
GET /v1/drugs/e981a9bf-37ca-4812-b04d-006a61bd56bc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "95",
  "substance": "PHENAZOPYRIDINE HYDROCHLORIDE",
  "productndc": "70000-0243",
  "dosage_form": "TABLET",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": null,
  "marketing_category": "UNAPPROVED DRUG OTHER"
}

See everything about phenazopyridine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.